Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Vervliet, Tim ^a   Lemmens, Irma ^b   Vandermarliere, Elien ^b   Decrock, Elke ^b   Ivanova, Hristina ^a   Monaco, Giovanni ^a   Sorrentino, Vincenzo ^c   Kasri, Nael Nadif ^d   Missiaen, Ludwig ^a   Martens, Lennart ^b   De Smedt, Humbert ^a   Leybaert, Luc ^b   Parys, Jan B ^a   Tavernier, Jan ^b   Bultynck, Geert ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF SIENA   (Italy)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PROTEIN BCL X; PROTEIN BINDING; RYANODINE RECEPTOR;

CELL LINE; CHEMISTRY; ENDOPLASMIC RETICULUM; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN CONFORMATION; PROTEIN DOMAIN;

BCL-X PROTEIN; CALCIUM; CELL LINE; ENDOPLASMIC RETICULUM; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84928142792     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09641     Document Type: Article

References (60)

1. Brunelle, J. K. & Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122, 437-441 (2009).
2. Chipuk, J. E. & Green, D. R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18, 157-164 (2008).
3. 21signaling, which do not depend on their putative pore-forming region. J Biol Chem 279, 54581-54589 (2004).
4. 21 handling in apoptosis. Cell Calcium 32, 413-420 (2002).
5. Monaco, G., Vervliet, T., Akl, H. & Bultynck, G. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond. Cell Mol Life Sci 70, 1171-1183 (2013).
6. Arbel, N., Ben-Hail, D. & Shoshan-Barmatz, V. Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem 287, 23152-23161 (2012).
7. Arbel, N. & Shoshan-Barmatz, V. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity. J Biol Chem 285, 6053-6062 (2010).
8. Plotz, M., Gillissen, B., Hossini, A. M., Daniel, P. T. & Eberle, J. Disruption of the VDAC2-Bak interaction by Bcl-xS mediates efficient induction of apoptosis in melanoma cells. Cell Death Differ 19, 1928-1938 (2012).
9. Ferdek, P. E. et al.Anovel role for Bcl-2 in regulation of cellular calcium extrusion. Curr Biol 22, 1241-1246 (2012).
10. Kuo, T. H. et al. Modulation of endoplasmic reticulum calcium pump by Bcl-2. Oncogene 17, 1903-1910 (1998).
11. 21/H1 antiporter activity of human Bax inhibitor-1. Cell Calcium 47, 387-396 (2010).
12. Xu,Q. & Reed, J. C. Bax inhibitor-1, amammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell 1, 337-346 (1998).
13. Oakes, S. A. et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A 102, 105-110 (2005).
14. Rong, Y. P. et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol Cell 31, 255-265 (2008).
15. White, C. et al. The endoplasmic reticulum gateway to apoptosis by Bcl-XL modulation of the InsP3R. Nat Cell Biol 7, 1021-1028 (2005).
16. Vervliet, T. et al. Bcl-2 binds to and inhibits ryanodine receptors. J Cell Sci 127, 2782-2792 (2014).
17. Letai, A. G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8, 121-132 (2008).
18. Rong, Y. P., Barr, P., Yee, V. C. & Distelhorst, C.W. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. Biochim Biophys Acta 1793, 971-978 (2009).
19. 21 signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death Differ 19, 295-309 (2012).
20. Perez, H. L. et al. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. Bioorg Med Chem Lett 22, 3946-3950 (2012).
21. Manion,M. K. et al. Bcl-XLmutations suppress cellular sensitivity to antimycinA. J Biol Chem 279, 2159-2165 (2004).
22. Eyckerman, S. et al. Design and application of a cytokine-receptor-based interaction trap. Nat Cell Biol 3, 1114-1119 (2001).
23. Martin, C., Chapman, K. E., Seckl, J. R. & Ashley, R. H. Partial cloning and differential expression of ryanodine receptor calcium-release channel genes in human tissues including the hippocampus and cerebellum. Neuroscience 85, 205-216 (1998).
24. Shimizu, S., Konishi, A., Kodama, T. & Tsujimoto, Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci U S A 97, 3100-3105 (2000).
25. 21 uptake. J Biol Chem 288, 19870-19881 (2013).
26. 21 at subcellular resolution using CEPIA. Nat Commun 5, 4153 (2014).
27. 21 signals to mitochondria. J Biol Chem Epub ahead of print (2015).
28. Boisguerin, P. et al. Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries in vivo. J Control Release 156, 146-153 (2011).
29. Ono, M. et al. BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts. Eur J Cardiothorac Surg 27, 117-121 (2005).
30. Sugioka, R. et al. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 22, 8432-8440 (2003).
31. Cantara, S., Donnini, S., Giachetti, A., Thorpe, P. E. & Ziche, M. Exogenous BH4/Bcl-2 peptide reverts coronary endothelial cell apoptosis induced by oxidative stress. J Vasc Res 41, 202-207 (2004).
32. Cantara, S., Thorpe, P. E., Ziche, M. & Donnini, S. TAT-BH4 counteracts Abeta toxicity on capillary endothelium. FEBS Lett 581, 702-706 (2007).
33. Hotchkiss, R. S. et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsisinduced lymphocyte apoptosis in vivo. J Immunol 176, 5471-5477 (2006).
34. McConnell, K. W. et al. Anti-apoptotic peptides protect against radiation-induced cell death. Biochem Biophys Res Commun 355, 501-507 (2007).
35. Santamaria, B. et al. Bcl-xL prevents peritoneal dialysis solution-induced leukocyte apoptosis. Perit Dial Int 28 Suppl 5, S48-52 (2008).
36. Klein, D. et al. Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem Biophys Res Commun 323, 473-478 (2004).
37. Martorana, F. et al. The BH4 domain of Bcl-XL rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum Mol Genet 21, 826-840 (2012).
38. 21 signaling and EC-coupling. Biochim Biophys Acta 1833, 866-875 (2013).
39. Marengo, J. J., Hidalgo, C. & Bull, R. Sulfhydryl oxidation modifies the calcium dependence of ryanodine-sensitive calcium channels of excitable cells. Biophys J 74, 1263-1277 (1998).
40. Xu, L., Eu, J. P., Meissner, G. & Stamler, J. S. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279, 234-237 (1998).
41. 21 leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49, 1722-1732 (2007).
42. Oda, T. et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 111, 3400-3410 (2005).
43. Islam,M. S.Calciumsignaling in the islets. Adv Exp Med Biol 654, 235-259 (2010).
44. Lanner, J. T., Georgiou, D. K., Joshi, A. D. & Hamilton, S. L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2, a003996 (2010).
45. 21 handling in excitable cells in health and disease. Pharmacol Rev 63, 700-727 (2011).
46. Van Petegem, F. Ryanodine receptors: structure and function. J Biol Chem 287, 31624-31632 (2012).
47. 21 in malignant hyperthermia and central core disease. Biochem Biophys Res Commun 322, 1256-1266 (2004).
48. Robinson, R., Carpenter, D., Shaw, M. A., Halsall, J. & Hopkins, P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27, 977-989 (2006).
49. Blayney, L. M. & Lai, F. A. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther 123, 151-177 (2009).
50. Marx, S. O. & Marks, A. R. Dysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseases. J Mol Cell Cardiol 58, 225-231 (2013).
51. 21 handling and arrhythmogenesis. Circ Res 108, 871-883 (2011).
52. Bruno, A. M. et al. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 33, 1001 e1001-1006 (2012).
53. Del Prete, D., Checler, F. & Chami, M. Ryanodine receptors: physiological function and deregulation in Alzheimer disease. Mol Neurodegener 9, 21 (2014).
54. Liu, J. et al. The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels (Austin) 8, 230-242 (2014).
55. Chen, X. et al. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener 6, 81 (2011).
56. 21 signals in HEK 293 cells. J Cell Sci 115, 2497-2504 (2002).
57. Eyckerman, S., Broekaert, D., Verhee, A., Vandekerckhove, J. & Tavernier, J. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett 486, 33-37 (2000).
58. Nadif Kasri, N., Nakano-Kobayashi, A. & Van Aelst, L. Rapid synthesis of the Xlinked mental retardation protein OPHN1 mediates mGluR-dependent LTD through interaction with the endocytic machinery. Neuron 72, 300-315 (2011).
59. Lemmens, I. et al. Heteromeric MAPPIT: a novel strategy to study modificationdependent protein-protein interactions in mammalian cells. Nucleic Acids Res 31, e75 (2003).
60. 21 signaling in Calcium Techniques: A Laboratory Manual (ed. Parys, J. B., Bootman,M., Yule,D. I. & Bultynck, G.) 93-112 (Cold SpringHarbor, 2014).